Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Rating of “Buy” by Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $48.40.

Several research analysts have weighed in on the stock. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target on the stock. BTIG Research initiated coverage on Ascentage Pharma Group International in a report on Monday, November 10th. They issued a “buy” rating and a $50.00 target price on the stock. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Finally, Truist Financial set a $51.00 price objective on Ascentage Pharma Group International in a research note on Monday, November 24th.

Institutional Trading of Ascentage Pharma Group International

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $96,000. ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the third quarter worth about $204,000. Chevy Chase Trust Holdings LLC purchased a new stake in shares of Ascentage Pharma Group International during the second quarter worth about $227,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Finally, Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000.

Ascentage Pharma Group International Trading Up 1.4%

NASDAQ AAPG opened at $24.52 on Friday. The company has a 50-day moving average price of $27.52 and a 200-day moving average price of $34.22. Ascentage Pharma Group International has a 52 week low of $17.09 and a 52 week high of $48.45. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.